Novo Nordisk's weight-loss drug Wegovy has been approved for sale in China. The approval opens up a significant market for the Danish pharmaceutical company, as China is estimated to have the highest number of overweight or obese people globally, with around 175 million overweight individuals. Novo Nordisk plans to initially target Chinese patients willing to pay out-of-pocket for the weekly injectable drug. Following the approval, Novo Nordisk's shares rose 4% to hit a new record high, with a 1.8% increase pre-market. This move also sets the stage for competition with other obesity drugs, including a new drug co-developed by China’s Innovent Biologics Inc. and Eli Lilly & Co. that has shown significant weight loss in late-stage trials. Despite the approval, Novo Nordisk promises existing patients priority amid shortages. In 2022, the proportion of overweight and obese adults in China reached almost 51% of the country's 1.4 billion people.
Drugmaker Novo Nordisk will limit the launch of its obesity treatment Wegovy in China to avoid disruption https://t.co/MwkGvO6TqO
Novo Nordisk’s Wegovy may just have two years to take over China’s market for weight loss drugs. https://t.co/XLqdE5R56B
Danish drugmaker Novo Nordisk said Tuesday that its injectable weight-loss drug Wegovy has been approved in China, where the proportion of overweight and obese adults reached almost 51% of the country's 1.4 billion people in 2022. #health https://t.co/49VgfIAlRb
China has approved Novo Nordisk’s obesity drug Wegovy, opening the drug up to a massive new market. Learn more in a new edition of The Readout newsletter: https://t.co/LFgd0cwIN3
$NVO's Wegovy weight loss drug gets approval in China. Mizuho healthcare equity strategist Jared Holz joins Yahoo Finance to discuss: https://t.co/8x8Vzqxun0
Novo Nordisk scored approval to sell its Wegovy weight loss drug in China. That’s a big win, but competitors will soon flood in. With shortages already widespread, can Novo Nordisk make the most of the opportunity? https://t.co/SKNpNKNHrx
The scale of China's obesity problem is seriously underappreciated. Over 30% of adults are now overweight and close to 20% are obese, and this will only increase. Novo Nordisk and other manufacturers of weight-loss drugs are going to make a killing in China. https://t.co/kwkbCvz2mZ
Novo Nordisk weight loss drug Wegovy approved in China https://t.co/MtBpku7w5D
#NovoNordisk’s flagship weight-loss drug #Wegovy has been approved for use in China, the Danish pharmaceutical giant says. https://t.co/exaAU0uMFK
Novo Nordisk gains approval to sell weight-loss drug Wegovy in China https://t.co/7D2Zf4sg4r
Blockbuster obesity drug Wegovy has been approved in China, opening the door for maker Novo Nordisk to begin selling it in the world’s second-largest economy, where the appetite for similar treatments is surging. @domchopping https://t.co/Uh90JYdyUB
Wegovy Approved In China—But Novo Nordisk Promises Existing Patients Priority Amid Shortages https://t.co/0vq91vUBHN
China is an open goal for Novo Nordisk’s obesity drug https://t.co/CfecVjQFt0 via @FT
Novo Nordisk’s blockbuster weight-management drug Wegovy has won approval, opening up competition for next-generation obesity drugs in China https://t.co/mzX7hLCMT5
Novo Nordisk wins approval in China for GLP-1 obesity drug Wegovy https://t.co/HvRhqe81uK
WATCH: China approved the sale of popular weight-loss drug Wegovy, according to Novo Nordisk. The Danish drugmaker said in March it would initially target Chinese patients willing to pay out-of-pocket for the weekly injectable drug https://t.co/8RDLafQAMQ https://t.co/2hpe0vAbAg
Wegovy, the weight-loss drug developed by Novo Nordisk, was approved for sale in China, opening up a new frontier for the Danish pharmaceutical company. https://t.co/JNd29z9PWn
⚠️ JUST IN: *NOVO NORDISK SHARES JUMP 4% TO HIT NEW RECORD HIGH AS WEGOVY GETS APPROVAL IN CHINA ARE YOU BUYING OR SELLING? $NVO https://t.co/n5ugypCcym
Novo Nordisk's hugely popular weight-loss drug Wegovy has been approved in China, it said on Tuesday, the world's second-largest economy and the country estimated to hold the highest number of overweight or obese people. https://t.co/sfw8uINb5b https://t.co/sfw8uINb5b
China approved the sale of popular weight-loss drug Wegovy, according to Novo Nordisk. The Danish drugmaker said in March it would initially target Chinese patients willing to pay out-of-pocket for the weekly injectable drug https://t.co/Vp5InJQXzc https://t.co/rV14rgjQf5
The Chinese approve Novo’s GLP1 drugs. Apparently there are around 175 mil overweight people in China. That massive. (Literally) Huge new market for $nvo
The Chinese approves Novo’s GLP1 drugs. Apparently there are around 175 mil overweight people in China. That massive. (Literally) Huge new market for $nvo
Novo Nordisk's Wegovy weight-loss drug approved in China https://t.co/lh1XoaoGTG
Novo Nordisk's Wegovy Weight-Loss Drug Approved in China, Shares Rise 1.8% Pre-Market https://t.co/irF4N66ylu
Wegovy got approval in China $NVO https://t.co/b9GocvQSP2
Novo Nordisk Shares Hit New Record As Wegovy Gets Approval In China https://t.co/EhAAx8dFA6
Novo Nordisk's weight loss drug Wegovy has been approved in China, the country estimated to have the highest number of overweight or obese people. https://t.co/eUrdoKv5Vb
Novo Nordisk $NVO climbs after Wegovy weight-loss drug reportedly approved in China https://t.co/g9ROOvKpUW https://t.co/zgMLF6ToYM
WATCH: Novo Nordisk's hugely popular weight-loss drug Wegovy has been approved in China — the world's second-largest economy and the country estimated to have the highest number of overweight or obese people https://t.co/8RDLafR8Co https://t.co/CqUh76zno5
$NVO (+1.8% pre) Novo Nordisk's Wegovy weight-loss drug approved in China - Reuters https://t.co/D4uh74815C
China is an open goal for Novo Nordisk’s obesity drug https://t.co/qDJxE3SScP | opinion
A new #obesity drug co-developed by China’s Innovent Biologics Inc. and Eli Lilly & Co. has demonstrated significant #weightloss in a late stage trial, paying the way for its approval in the country to compete with the blockbuster from Novo Nordisk A/S. https://t.co/rAijcbXI87
China offers open goal for Novo Nordisk’s weight loss drug https://t.co/zX8zE7dzNf
Novo Nordisk $NVO said today its weight loss drug Wegovy has been approved in China 🇨🇳 for long-term weight management - CNBC https://t.co/nvvmr6lCV8